tirzepatide vs semaglutide dosing SURPASS-2 (NEJM 2021) was the definitive head-to-head: 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Switching from Semaglutide to Tirzepatide:

Retatrutide: The Three Receptors It Targets and Why It Matters Retatrutide affects three key hormonal receptors GLP-1R, GIPR, and GCGR making it a novel investigational triple receptor agonist developed by Eli Lilly

It might mean changing the agonist profile to engage slightly different receptor pathways

Reduced efficacy concerns GLP-1 receptor agonists are designed to work at specific doses to achieve optimal receptor activation (saturation) and to provide full therapeutic effect

Well, the difference is that Retatrutide is designed to work on multiple hormones at one time, 3 to be exact!, making it a powerful and more comprehensive solution for weight management